The value of regulatory interactions developing a new modality in gene therapy- presentation at ISCT Paris May 31 - June 3
The NMMP program aims to improve scientific networks and collaborations across Sweden, as well as to increase the awareness and accessibility of the cutting-edge infrastructure at SciLifeLab
Abstract: The Value of early Regulatory Interactions with Authorities for emilimogene sigulactibac (INN) - a new modality in gene therapy, to be presented by Margareth Jorvid Head of Regulatory Affairs
Conference topic is to - Reimagine the future of therapeutics
Bioprocessing and analytics industry business expert to spearhead major growth drive